As one of the leading global manufacturers of insulins, Biocon Biologics is committed to enable access to world-class affordable insulins to patients in Malaysia. The Company has been working closely with the Ministry of Health, Malaysia (MoH) to cater to the growing needs of diabetes patients in the country and reducing the dependency on insulin imports. Since 2016, Biocon Biologics has provided the MoH over 87 million insulin cartridges and has served the needs of nearly 300,000 people with diabetes in Malaysia.

Following Biocon’s entry into Malaysia, prices of human insulin have dropped by over 40% and insulinization has also improved by 30%, according to a market study.

Biocon Biologics has made considerable progress on the second phase of the Malaysia facility, having invested an additional USD 250 million (MYR 1,102.5 million) in 2023 on expansion. Once ready, it will double the company’s capacity thus enabling it to cater to the additional demands for human insulin and insulin glargine.

In addition to the U.S. FDA, EMA, the manufacturing facility in Johor is approved by NPRA, Malaysia, TGA (Australia), ANVISA (Brazil), etc. The facility has state-of-the-art R&D, Quality Assurance, Quality Control labs and a very robust Quality Management System, which ensures the quality of products manufactured at the facility.

As one of the leading, global manufacturers of insulins, Biocon Biologics is benefiting millions of patients in Malaysia and other countries through its scientifically validated, high-quality human insulin and analog products manufactured at the facility. Biocon Biologics has cumulatively supplied 7.3 bn doses of insulins (rh-Insulin + Insulin Glargine) globally till FY24.

The Company is driven by its mission to enable universal access to insulins, so that this basic therapy reaches those who need them the most. Biocon Biologics aspires to reach ‘one in five’ insulin-dependent people with diabetes globally and it is consistently working towards this mission.

In anticipation of the increase in demand for insulins, Biocon Biologics had started expanding capacity in Malaysia in 2023 with an additional investment of USD 250 million (MYR 1,102.5 million). The Phase 2 investments will double the Company’s capacity, thus enabling it to cater to the additional demands for human insulin and Insulin Glargine.

Biocon Biologics has around 800 employees in Malaysia, involved in various aspects of the insulin production process, from research and development to manufacturing and quality control. The facility is known for its high standards and innovative approaches, which are driven by a dedicated team of professionals committed to improving patient outcomes.

The Malaysia team comprises people from diverse nationalities and cultural backgrounds, and includes experts in biotechnology, engineering, quality assurance, and regulatory affairs. The Company emphasizes a culture of innovation and continuous improvement, providing its employees with opportunities for professional growth and development.

Biocon Biologics Malaysia fosters a collaborative, inclusive, and innovation-driven work culture, offering mentorship programs, training initiatives, and prioritizing diversity in hiring practices.

Biocon Biologics actively encourages its employees in Malaysia to participate in various volunteering activities through the Biocon Malaysia Volunteer Community (BMVC).

The Malaysia team has planted saplings, cleaned beaches, restored mangroves and fed the homeless, bringing hope and healing to the planet and its people.

Biocon Malaysia volunteers collaborated with the Kechara Soup Kitchen (KSK), a non-profit organization, to distribute food to the homeless and collect surplus food from supermarkets for redistribution, effectively reducing food wastage.

They also participated in healthcare initiatives with the Johor Outreach & Community Centre, providing mobile clinic services to refugees and underserved populations.

The Biocon Biologics Malaysia team is making continuous investment in responsible and sustainable business practices that help create a healthier planet. The employees are deeply committed to biodiversity and land conservation.

As part of the Malaysia Biologics Woodlands Project, employees planted more than a thousand trees in collaboration with local authorities. They also joined the Desaru Bebas Plastic initiative, a collaborative effort supported by the Pengerang Municipal Council, to remove over 230 kilograms of waste from the Tanjung Balau waterway shorelines.

The team’s efforts and their impact were recognized at the 9th edition of the Sustainability & CSR Malaysia Awards 2024, where they won the prestigious Company of the Year (Biotechnology Manufacturing) award.